Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by INmune Bio, Inc.

< Previous 1 2 Next >
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.